Learn more about clinical trials for your Castleman disease patients.
As part of our mission to improve care and survival of patients with Castleman disease, the CDCN aims to support and educate the community about Castleman disease clinical trials and facilitate the research that forms the basis for clinical trials.
Currently, there are five clinical trials for Castleman disease, however the Sirolimus and BCD regimen trials have recently closed for enrollment.
Dr. Frits van Rhee, Principal Investigator, University of Arkansas
Sirolimus Clinical Trial, USA
We recently completed our clinical trial for patients with idiopathic multicentric Castleman disease at the University of Pennsylvania and University of Arkansas for Medical Sciences to evaluate the medication sirolimus. The trial analyzed idiopathic multicentric Castleman disease patients that did not sufficiently get better with, or relapsed on, anti-IL6 treatment (siltuximab or tocilizumab). This trial is now closed to enrollment. Please visit cdcn.org/trial in the future for upcoming trial information or email CDtrial@pennmedicine.upenn.edu for more information.
BCD Regimen Clinical Trial, China
The Peking Union Medical College Hospital in Beijing, China has recently stopped recruiting for a clinical trial that is exploring the effectiveness and safety of the medications bortezomib, cyclophosphamide and dexamethasone (BCD regimen). The trial assessed patients who were newly diagnosed with idiopathic multicentric Castleman disease. More information about this trial can be found here.
Anti-IL-6R mAb Injection Trial, China
The Peking Union Medical College Hospital in Beijing, China is currently recruiting for a clinical trial that is exploring the safety and tolerability of recombinant humanized anti-interleukin-6 receptor monoclonal antibody (Anti-IL-6R mAb) injection in patients with iMCD. More information about this trial can be found here.
Zanuburutinib Trial, China
The Peking Union Medical College Hospital in Beijing, China is currently recruiting for a clinical trial that is exploring the effectiveness and safety of Zanuburutinib in relapsed and refractory iMCD patients. More information about this trial can be found here.
Pacritinib Trial, USA
The National Institutes of Health in Maryland, USA is currently recruiting for a clinical trial that is testing the medication pacritinib in patients with KSHV-MCD. More information about this trial can be found here.